Bylantra (devimistat) / Cornerstone Pharma, Ono Pharma  >>  Phase 1
Welcome,         Profile    Billing    Logout  

6 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Bylantra (devimistat) / Cornerstone Pharma, Ono Pharma
NCT01835041: CPI-613 and Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer

Completed
1
21
US
6,8-bis(benzylthio)octanoic acid, alpha-lipoic acid analogue CPI-613, CPI-613, oxaliplatin, 1-OHP, Dacotin, Dacplat, Eloxatin, L-OHP, leucovorin calcium, CF, CFR, LV, irinotecan hydrochloride, Campto, Camptosar, CPT-11, irinotecan, U-101440E, fluorouracil, 5-fluorouracil, 5-Fluracil, 5-FU, laboratory biomarker analysis
Wake Forest University Health Sciences, National Cancer Institute (NCI)
Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage IV Pancreatic Cancer
02/17
03/23
NCT02484391: CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Granulocytic Sarcoma

Completed
1
49
US
6,8-Bis(benzylthio)octanoic Acid, Alpha-Lipoic Acid Analogue CPI-613, CPI 613, CPI-613, Cytarabine, .beta.-Cytosine arabinoside, 1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-.beta.-D-Arabinofuranosylcytosine, 1.beta.-D-Arabinofuranosylcytosine, 2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-, Alexan, Ara-C, ARA-cell, Arabine, Arabinofuranosylcytosine, Arabinosylcytosine, Aracytidine, Aracytin, Aracytine, Beta-Cytosine Arabinoside, CHX-3311, Cytarabinum, Cytarbel, Cytosar, Cytosar-U, Cytosine Arabinoside, Cytosine-.beta.-arabinoside, Erpalfa, Starasid, Tarabine PFS, U 19920, U-19920, Udicil, WR-28453, Hematopoietic Cell Transplantation, HCT, Hematopoietic Stem Cell Transplantation, HSCT, stem cell transplantation, Mitoxantrone Hydrochloride, CL 232315, DHAD, DHAQ, Dihydroxyanthracenedione Dihydrochloride, Mitoxantrone Dihydrochloride, Mitoxantroni Hydrochloridum, Mitozantrone Hydrochloride, Mitroxone, Neotalem, Novantrone, Onkotrone, Pralifan
Wake Forest University Health Sciences, National Cancer Institute (NCI)
Granulocytic Sarcoma, Recurrent Adult Acute Myeloid Leukemia
10/18
02/22
NCT02232152: CPI-613 and Fluorouracil in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed by Surgery

Completed
1
19
US
6,8-bis(benzylthio)octanoic acid, alpha-lipoic acid analogue CPI-613, CPI-613, fluorouracil, 5-fluorouracil, 5-Fluracil, 5-FU, pharmacological study, pharmacological studies, laboratory biomarker analysis
Wake Forest University Health Sciences, National Cancer Institute (NCI)
Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer, Signet Ring Adenocarcinoma of the Colon, Signet Ring Adenocarcinoma of the Rectum, Stage IIIA Colon Cancer, Stage IIIA Rectal Cancer, Stage IIIB Colon Cancer, Stage IIIB Rectal Cancer, Stage IIIC Colon Cancer, Stage IIIC Rectal Cancer, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVB Colon Cancer, Stage IVB Rectal Cancer
02/19
01/23
NCT02168140: CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma

Completed
1
16
US
6,8-bis(benzylthio)octanoic acid, alpha-lipoic acid analogue CPI-613, CPI-613, bendamustine hydrochloride, bendamustin hydrochloride, bendamustine, cytostasan hydrochloride, Treanda
Wake Forest University Health Sciences, National Cancer Institute (NCI)
Adult Lymphocyte Depletion Hodgkin Lymphoma, Adult Lymphocyte Predominant Hodgkin Lymphoma, Adult Mixed Cellularity Hodgkin Lymphoma, Adult Nasal Type Extranodal NK/T-cell Lymphoma, Adult Nodular Sclerosis Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Hepatosplenic T-cell Lymphoma, Noncutaneous Extranodal Lymphoma, Peripheral T-cell Lymphoma, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, T-cell Adult Acute Lymphoblastic Leukemia, T-cell Large Granular Lymphocyte Leukemia
04/19
09/22
NCT05070104: CPI-613 (Devimistat) in Combination With Modified FOLFIRINOX Plus Bevacizumab in Patients With Metastatic Colorectal Cancer

Withdrawn
1
12
NA
CPI-613, Devimistat, modified FFX, Bevacizumab
Cornerstone Pharmaceuticals
C04.588.274.476.411.307
03/24
11/24
NCT05325281: CPI-613 (Devimistat) in Combination With Chemoradiation in Patients With Pancreatic Adenocarcinoma

Recruiting
1
24
US
CPI-613® (Dose level -1.0 250 mg/m^2), Devimistat, alpha-lipoic acid analogue CPI-613, CPI-613® (Dose level 1.0 500 mg/m^2), CPI-613® (Dose level 2.0 1,000 mg/m^2), CPI-613® (Dose level 3.0 1,500 mg/m^2), CPI-613® Maximum Tolerated Dose (MTD), Gemcitabine, Gemzar®, Intensity-modulated Radiation Therapy
Medical College of Wisconsin, Cornerstone Pharmaceuticals, Barbara Ann Karmanos Cancer Institute
Pancreas Adenocarcinoma
08/26
08/27

Download Options